Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

doi:10.1038/s41598-019-47627-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.

Scientific reports - 8 Aug 2019

Ruzzo Annamaria, Graziano Francesco, Galli Francesca, Galli Fabio, Rulli Eliana, Lonardi Sara, Ronzoni Monica, Massidda Bruno, Zagonel Vittorina, Pella Nicoletta, Mucciarini Claudia, Labianca Roberto, Ionta Maria Teresa, Bagaloni Irene, Veltri Enzo, Sozzi Pietro, Barni Sandro, Ricci Vincenzo, Foltran Luisa, Nicolini Mario, Biondi Edoardo, Bramati Annalisa, Turci Daniele, Lazzarelli Silvia, Verusio Claudio, Bergamo Francesca, Sobrero Alberto, Frontini Luciano, Magnani Mauro

Abstract excerpt

Polymorphisms contribute to inter-individual differences and show a promising predictive role for chemotherapy-related toxicity in colon cancer (CC). TOSCA is a multicentre, randomized, non-inferiority, phase III study conducted in high-risk stage II/stage III CC patients treated with 6 vs 3 months of FOLFOX-4 or XELOX adjuvant chemotherapy. During this post-hoc analysis, 218 women and 294 men were genotyped for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Chemotherapy, Adjuvant

Share to Fluorouracil

Share to Leucovorin

Share to Multidrug Resistance-Associated Protein 2

Share to Organoplatinum Compounds

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 31395900
DOI: 10.1038/s41598-019-47627-1
PMCID: PMC6687727

Genes

TTN
ABCC1
ABCC2
ERCC1
GSTM1
GSTP1
GSTT1
MTHFR
TYMS
XRCC1
XRCC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.PMID 31395900Read ↗

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.Semantic proximity Read ↗

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Semantic proximity Read ↗

Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.Semantic proximity Read ↗

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.Semantic proximity Read ↗

Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.Semantic proximity Read ↗

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survivalSemantic proximity Read ↗

Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.Semantic proximity Read ↗

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant ChemotherapySemantic proximity Read ↗

Genetic susceptibility variants associated with colorectal cancer prognosis.Semantic proximity Read ↗

Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.Semantic proximity Read ↗

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.